GF Fund Management CO. LTD. Raises Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

GF Fund Management CO. LTD. boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 22.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,544 shares of the biotechnology company’s stock after purchasing an additional 278 shares during the quarter. GF Fund Management CO. LTD.’s holdings in Ascendis Pharma A/S were worth $241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $28,000. Jones Financial Companies Lllp increased its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Quarry LP purchased a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $96,000. Tower Research Capital LLC TRC lifted its stake in Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 664 shares during the last quarter. Finally, New Wave Wealth Advisors LLC bought a new stake in Ascendis Pharma A/S during the first quarter worth about $222,000.

Ascendis Pharma A/S Trading Up 0.6%

Shares of NASDAQ:ASND opened at $174.07 on Friday. The company has a 50-day moving average price of $167.68 and a 200-day moving average price of $152.26. The company has a market cap of $10.64 billion, a price-to-earnings ratio of -27.72 and a beta of 0.38. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

ASND has been the subject of a number of recent research reports. Evercore ISI boosted their target price on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a research note on Thursday. They issued an “overweight” rating and a $250.00 price objective for the company. Oppenheimer reiterated an “outperform” rating and issued a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Finally, Royal Bank Of Canada raised their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $220.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.